Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 3
2014 3
2015 3
2016 8
2017 4
2018 6
2019 8
2020 8
2021 10
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Penson RT, Stover EH, Curtis J, Sawyer H, Polak M, Chowdhury D, D'Andrea AD, Färkkilä A, Shapiro GI, Matulonis UA. Konstantinopoulos PA, et al. Among authors: farkkila a. JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635. JCO Precis Oncol. 2024. PMID: 38635934 Clinical Trial.
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer.
Launonen IM, Erkan EP, Niemiec I, Junquera A, Hincapié-Otero M, Afenteva D, Liang Z, Salko M, Szabo A, Perez-Villatoro F, Falco MM, Li Y, Micoli G, Nagaraj A, Haltia UM, Kahelin E, Oikkonen J, Hynninen J, Virtanen A, Nirmal AJ, Vallius T, Hautaniemi S, Sorger P, Vähärautio A, Färkkilä A. Launonen IM, et al. Among authors: farkkila a. bioRxiv [Preprint]. 2024 Mar 20:2024.03.19.585657. doi: 10.1101/2024.03.19.585657. bioRxiv. 2024. PMID: 38562799 Free PMC article. Preprint.
Tracing back primed resistance in cancer via sister cells.
Dai J, Zheng S, Falco MM, Bao J, Eriksson J, Pikkusaari S, Forstén S, Jiang J, Wang W, Gao L, Perez-Villatoro F, Dufva O, Saeed K, Wang Y, Amiryousefi A, Färkkilä A, Mustjoki S, Kauppi L, Tang J, Vähärautio A. Dai J, et al. Among authors: farkkila a. Nat Commun. 2024 Feb 7;15(1):1158. doi: 10.1038/s41467-024-45478-7. Nat Commun. 2024. PMID: 38326354 Free PMC article.
Dysregulated germinal center reaction with expanded T follicular helper cells in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy lymph nodes.
Hetemäki I, Sarkkinen J, Heikkilä N, Drechsel K, Mäyränpää MI, Färkkilä A, Laakso S, Mäkitie O, Arstila TP, Kekäläinen E. Hetemäki I, et al. Among authors: farkkila a. J Allergy Clin Immunol. 2023 Dec 19:S0091-6749(23)02454-5. doi: 10.1016/j.jaci.2023.12.004. Online ahead of print. J Allergy Clin Immunol. 2023. PMID: 38128835 Free article.
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UM, Lassus H, Hautaniemi S, Färkkilä A, Hynninen J, Hietanen S, Carpén O, Kauppi L. Pikkusaari S, et al. Among authors: farkkila a. Clin Cancer Res. 2023 Aug 15;29(16):3110-3123. doi: 10.1158/1078-0432.CCR-22-3156. Clin Cancer Res. 2023. PMID: 36805632 Free PMC article.
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, Konstantinopoulos PA, Matulonis U, Yu H, Zhao JJ. Ding L, et al. Among authors: farkkila a. J Immunother Cancer. 2023 Jan;11(1):e005627. doi: 10.1136/jitc-2022-005627. J Immunother Cancer. 2023. PMID: 36609487 Free PMC article.
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
Perez-Villatoro F, Oikkonen J, Casado J, Chernenko A, Gulhan DC, Tumiati M, Li Y, Lavikka K, Hietanen S, Hynninen J, Haltia UM, Tyrmi JS, Laivuori H, Konstantinopoulos PA, Hautaniemi S, Kauppi L, Färkkilä A. Perez-Villatoro F, et al. Among authors: farkkila a. NPJ Precis Oncol. 2022 Dec 29;6(1):96. doi: 10.1038/s41698-022-00339-8. NPJ Precis Oncol. 2022. PMID: 36581696 Free PMC article.
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.
Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA, Zamarin D, Pépin D, D'Andrea AD, Färkkilä A, Cubillos-Ruiz JR. Chae CS, et al. Among authors: farkkila a. Cancer Discov. 2022 Aug 5;12(8):1904-1921. doi: 10.1158/2159-8290.CD-21-1181. Cancer Discov. 2022. PMID: 35552618 Free PMC article.
56 results